Regions – Page 45 – pharmaceutical daily

September 29, 2021 Off

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life

Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.

September 20, 2021 Off

Cellbox Solutions kicks off subsidiary in the USA

By Dino Mustafić

Cellbox Solutions GmbH, developer of the patented Cellbox technology, has founded their U.S. company and is now selling products directly to the U.S./North American market.

September 20, 2021 Off

Santhera nets CHF 45 Million in funding

By Dino Mustafić

Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.

September 20, 2021 Off

Oncimmune to evaluate autoantibody profiles

By Dino Mustafić

Oncimmune Holdings has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.

September 20, 2021 Off

Novartis, Harmonia move to Phase III trial to test Kisqali vs. Ibrance in patients with advanced breast cancer

By Dino Mustafić

Novartis said Monday it has started a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase III, multicenter, open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib),.

September 13, 2021 Off

MGC Pharmaceuticals granted UK Import permit for CannEpil+

By Dino Mustafić

CannEpil+ , based on CannEpil, designed by MGC Pharma to treat Refractory Epilepsy, has been approved for import into the UK by the Medicines and Healthcare products Regulatory Agency via its UK distribution and clinical access partner Elite Pharmaco.

September 13, 2021 Off

USFDA accepts Novartis’ tislelizumab for people with esophageal cancer

By Dino Mustafić

Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.

August 26, 2021 Off

Vaccination with certain Moderna vaccines suspended in Japan after contamination reports

By Dino Mustafić

Japan has suspended more than 1.5 milion doses of Moderna vaccine after getting contamination reports

August 26, 2021 Off

MGC Pharmaceuticals in its first USA supply agreement for its phytocannabinoid products

By Dino Mustafić

MGC Pharmaceuticals, a specialist in phytocannabinoid-derived medicines, has signed a binding US Market Supply and Distribution Agreement with US-based AMC Holdings, with minimum orders of $24 million for MGC products including CannEpil®, CogniCann® and CimetrA™ over the initial 3 year period.

July 23, 2021 Off

Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

By BusinessWire

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine.